CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present preclinical research on two novel potential cancer therapies, MM-398 and MM-141, and an innovative platform for biomarker analysis at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place on October 19-23, 2013 at the Hynes Convention Center in Boston, Massachusetts. Presentations will include preclinical studies of MM-398, a nanolipsomal encapsulated form of irinotecan, and MM-141, a bispecific antibody co-targeting IGF-1R and ErbB3, and their activity in tumor models. Data will be shared in three poster sessions.
- Session Title: Novel Assay Technology 1 A205: Development and application of a platform for analysis of protein biomarkers in clinical biopsies of limited quantity Sunday, October 20, 2013, 12:30 PM – 7:30 PM Exhibit Hall C-D
- Session Title: Tumor Microenvironment AC293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model Tuesday, October 22, 2013, 12:30 PM – 7:30 PM Exhibit Hall C-D
- Session Title: Monoclonal Antibodies C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormone therapy-resistant ER/PR+ breast cancer Tuesday, October 22, 2013, 12:30 PM – 7:30 PM Exhibit Hall C-D
CONTACT: Media Contacts: Debbie Tseng, Merrimack 617-441-7659 email@example.com Heather Gitlitz, Spectrum 202-955-6222 firstname.lastname@example.org